Is t(11;14)(q13;q32) good or bad for newly diagnosed multiple myeloma?

All newly-diagnosed patients with MM (NDMM) treated at Peking University People's Hospital from January 2009 to December 2019 with fluorescence in-situ hybridization (FISH) proven t(11;14)(q13;q32) were enrolled in the study group. The study was approved by the Peking University People's Hospital Institutional Review Board (ID: 2021PHB299–001). There was no significant difference in gender, age, ISS stage, renal function damage, lactate dehydrogenase (LDH) level, platelet count, free light chain M-protein ratio, the proportion of PCs, G-banding abnormalities in the BM samples, and the incidence of extramedullary infiltration (P > 0.05) between the 1q21 positive and negative groups [Supplementary Tables 2, http://links.lww.com/CM9/B69 and 3, http://links.lww.com/CM9/B69]. Multivariate analysis showed that the gain/amp of 1q21 was an independent factor for PFS (P = 0.030, HR = 2.350, 95% CI: 1.343–4.112) and OS (P = 0.004, HR = 5.660, 95% CI: 1.725–18.575) in the t(11;14) positive NDMM.